Objectives Thymectomy has become recognized as an integral element in the treatment of patients with myasthenia gravis (MG). Although the incidence of elderlyonset MG has recently been increasing, there is little data demonstrating the efficacy and complications of thymectomy in this population. To clarify this point, we divided the thymectomized patients with MG into young and elderly groups, and retrospectively examined their clinical features and therapeutic outcomes.
Introduction
Myasthenia gravis (MG) is an autoimmune disorder caused by an antibody-mediated attack directed against acetylcholine receptors (AchR) at neuromuscular junctions, and clinically characterized by muscular weakness and easy fatigability. In this disease, the thymus has been regarded as the main site for the production of anti-AchR antibodies because approximately 75% of patients were shown to have histopathological abnormalities, including neoplasm and hyperplasia, in thymic tissues (1) . Although MG can develop at any age, two peaks have been recognized in its incidence: the twenties in women and, less consistently, the over-fifties in men (2, 3) . In recent decades, however, several reports have noted that the incidence of elderly-onset MG has been increasing in the United States and European countries (3) (4) (5) (6) (7) .
In the treatment of MG, thymectomy has generally been accepted as the standard therapy combined with the use of corticosteroid, immunosuppressive, and/or anti-cholinesterase agents. In elderly patients, however, the therapeutic efficacy of thymectomy remains controversial: some reports have emphasized a possible increase in surgical risks with aging (8-11), while others have described the effectiveness and safety of thymectomy even in elderly patients (12) (13) (14) (15) (16) (17) (18) . Here, we retrospectively reviewed MG patients who had been admitted to our hospital since 1988 in order to investigate the clinical features of elderly-onset MG, and also to evaluate the clinical benefits and complications of thymectomy in elderly patients.
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Patients and Methods

Patients
To evaluate the clinical benefits and disadvantages of thymectomy we reviewed 57 patients with MG (18 men and 39 women, mean age 45.3±17.9 years) who had been treated with this surgical procedure in our hospital from 1988 to 2002, since detailed pre-and post-operative data were available. The diagnosis of MG was made on the basis of the following findings: typical history, fluctuating weakness of voluntary muscles, a clearly positive response to the edrophonium chloride test and/or positive findings in electromyographic studies. Increase in serum levels of circulating anti-AchR antibodies also supported the diagnosis of MG. The patients were classified into young (younger than 60) and elderly (60 or older) groups according to the age of onset. Clinical information, including initial symptoms and the phenotype of MG according to Osserman's classification (19) , was obtained from medical records.
In these patients we compared the myasthenic severity scales (20) between before and after total thymectomy, and examined the duration from operation to discharge in order to evaluate the therapeutic effects and the risk of complications. Histopathology of the thymus was described according to the classification proposed by Aster and Kumar (21) .
Statistics
Data were analyzed using unpaired Student's t and Chisquare tests. To statistically evaluate the difference in myasthenic severity scales between before and after thymectomy, paired Student's t test was employed. The results represented the mean ± standard error where applicable, and the level of significance was p<0.05 in all analyses. Commercially available statistics software was used for data analysis (Microsoft Excel, Microsoft Corporation, NY, USA).
Results
Clinical profiles of the patients are summarized in Table  1 . The fifty-seven patients were classified into 36 young and 21 elderly according to the age of onset. Thymomaassociated patients occupied around 67% of the total number. Neither the young nor the elderly group showed any signifi- cant difference in the age of onset between with and without thymoma. In the initial manifestations and the phenotype of MG, ocular symptoms and Osserman's type II were most common in both groups irrespective of associated thymoma, respectively, and types III and IV were quite rare. Thymic histopathology of the thymoma-associated patients showed malignant thymoma in about 40% of the young patients and 38% of the elderly patients. Thymic hyperplasia was seen in around 73% of the young-onset MG patients without thymoma, whereas no patients in the elderly group showed this pathology. Before thymectomy no patient was treated with either prednisolone or plasmapheresis. After surgery, all patients were treated with combinations of other therapies, including anti-cholinesterase agents, prednisolone, and plasmapheresis, except for one. Oral prednisolone was initially given to MG patients at a dose of 30 mg/day, and gradually tapered for several years after thymectomy. In a 74-year-old male patient with thymoma who belonged to Osserman's type I, ocular symptoms achieved a complete remission after thymectomy with no additional treatment. Anti-cholinesterase agents and prednisolone were most commonly employed for the treatment of MG after thymectomy, and a total of 50 Gy of radiotherapy was given to the anterior mediastinum only in patients with invasive thymoma to reduce the risk of recurrence. No immunosuppressive agents, including tacrolimus, were used for treatment.
There were no serious complications during or after the thymectomy. The period of hospitalization from thymectomy to discharge in young and elderly patients with thymoma was 47.8±10.4 and 50.3±10.6 days, respectively, and no significant difference could be found between them. In young and elderly patients without thymoma the hospitalization was 27.9±5.7 and 39.3±8.2 days, respectively, and this difference also was not statistically significant. Both young and elderly patients with thymoma showed a slightly, but not significantly, longer hospitalization than those without thymoma, possibly because of radiotherapy. With respect to the therapeutic effects of thymectomy, myasthenic severity scales were increased after the operation in all patients irrespective of associated thymoma and the administration of oral prednisolone except in one patient (Fig. 1) . In a 47-year-old female MG patient with thymoma the myasthenic severity scale was decreased in parallel with worsening of limb weakness and general status after thymectomy possibly because of worsening of chronic renal failure. There were statistically significant increases in the myasthenic severity scales after thymectomy compared with before in young MG patients with (p<0.01) and without thymoma (p<0.001). Also in the elderly group both patients with and without thymoma showed significant improvement in myasthenic symptoms after thymectomy (p<0.005 and p<0.05, respectively).
Discussion
In general only 6-20% of MG patients have been considered to develop the disease after the age of 60 (22) (23) (24) . In several recent reports, however, the percentage of these elderly-onset patients with MG has gradually increased and reached around 30-60% in European countries and the United States (4, 7, 25) . There is a vast difference in the age distribution of MG between races, and it is well known that the number of elderly-onset MG patients is far fewer among the Chinese than among Caucasian people (26) ber of elderly patients with MG has increased, several immunological features have been reported in this group: the serum level of circulating anti-AchR antibodies is often lower in elderly-onset MG patients than in the young group (27, 28) , antibodies to titin can be found in around one half of the elderly patients (while the young group rarely shows a positive result for this antibody) (29) , and the development of MG is frequently associated with HLA-DRw3 in the young group and with DRw2 in elderly patients (30) . In the clinical aspect, including initial symptoms and the grade of disease, however, no significant differences have been found between the young-and elderly-onset groups irrespective of associated thymoma, as shown in the present study.
Thymectomy has been widely employed in the treatment of MG as a standard therapy, particularly for the generalized type. From the viewpoint of the histopathology of the thymus this surgical procedure is of course necessary in thymoma-associated cases. Also in young-onset patients with MG without thymoma this operation is usually selected because hyperplasia is predominantly seen in the histology of the thymus, and possibly plays an important role in the production of anti-AchR antibodies. In the present study around 73% of the young group without thymoma histologically showed thymic hyperplasia. In the elderly group without thymoma, however, thymectomy remains controversial. One reason is that thymic tissues in this group usually show abundant fat tissues without hyperplastic change. In general the thymus is gradually replaced with fat tissues after birth, and reduces in size without lymphoid follicles in parallel with aging in normal individuals. This change is designated as thymic atrophy or residual thymus. Also in elderly-onset MG patients without thymoma the thymus frequently seems atrophic on both microscopic and gross appearances despite the presence of architectural changes such as distended perivascular space and disrupted basement membrane (31) . The other reason is that thymectomy may be risky and unpleasant for elderly patients because of its many possible complications, including ischemic heart disease, osteoporosis and infection (8) (9) (10) (11) .
In the present study myasthenic severity scales significantly improved after thymectomy compared with before even in the elderly group, although all patients histologically showed thymic atrophy. According to several reports thymectomy clinically resulted in good therapeutic outcomes also in elderly-onset MG patients (12) (13) (14) (15) (16) (17) (18) , as shown in the present study. Particularly in recent reports, the clinical benefits and safety of thymectomy have been emphasized even in elderly-onset groups (14) (15) (16) (17) (18) , and this might largely be a result of progress in the management and care of the patients. Although the therapeutic effects of thymectomy could not be separately evaluated in the present study because of the administration of oral prednisolone in almost all of the elderly patients after the operation, no significant difference could be found in the duration from the surgical procedure to discharge between elderly and young patients with MG irrespective of associated thymoma, suggesting that thymectomy might at least cause no critical complications affecting recovery even in elderly patients.
In conclusion, at the present time thymectomy should be positively considered also in the treatment of elderly patients as it seems to show few critical complications in terms of therapeutic effects and procedural safety. Immunosuppressants alone have no reliable effects in controlling the myasthenic symptoms of MG and their harmful effects remain not inconsiderable in the long-term follow-up. In the future, however, the treatment of MG will hopefully be tailored according to the age and condition of each individual, particularly in elderly patients, and be accompanied by the development of new immunomediated therapies.
